Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 246

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Prolonged Administration of Azacitidine With or Without Entinostat for Myelodysplastic Syndrome and Acute Myeloid Leukemia With Myelodysplasia-Related Changes: Results of the US Leukemia Intergroup Trial E1905

Open access
Prebet, Thomas, Sun, Zhuoxin, Figueroa, Maria E., Ketterling, Rhett, Melnick, Ari, Greenberg, Peter L., Herman, James, Juckett, Mark, Wang, Eunice S., Smith, Mitchell R., Malick, Lisa, Paietta, Elisabeth, Czader, Magdalena, Litzow, Mark, Gabrilove, Janice, Erba, Harry P., Gore, Steven D., Tallman, Martin S. · 2014 · Journal of Clinical Oncology

Abstract

Purpose: Although azacitidine (AZA) improves survival in patients with high-risk myelodysplastic syndrome, the overall response remains approximately 50%. Entinostat is a histone deacetylase inhibitor that has been combined with AZA with significant clinical activity in a previous phase I dose finding study. Design: Open label phase II randomized trial comparing AZA 50 mg/m 2/d given for 10 days ± entinostat 4 mg/m 2/d day 3 and day 10. All subtypes of myelodysplasia, chronic myelomonocytic leukemia, and acute myeloid leukemia with myelodysplasia-related changes were eligible for the study. The primary objective was the rate of hematologic normalization (HN; complete remission + partial remission + trilineage hematological improvement). Results: One hundred forty-nine patients were analyzed, including 97 patients with myelodysplastic syndrome and 52 patients with acute myeloid leukemia. In the AZA group, 32% (95% CI, 22% to 44%) experienced HN and 27% (95% CI, 17% to 39%) in the AZA + entinostat group. Both arms exceeded the HN rate of historical control (Cancer and Leukemia Group B 9221 trial), but only the AZA group fulfilled the primary objective of the study. Rates of overall hematologic response were 46% and 44%, respectively. Median overall survivals were 18 months for the AZA group and 13 months for the AZA + entinostat group. The combination arm led to less demethylation compared with the monotherapy arm, suggesting pharmacodynamic antagonism. Conclusion: Addition of entinostat to AZA did not increase clinical response as defined by the protocol and was associated with pharmacodynamic antagonism. However, the prolonged administration of AZA by itself seems to increase HN rate compared with standard dosing and warrants additional investigation.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2013.50.3102

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 246

Metadata

Authors
Prebet, T., Sun, Z., Figueroa, M. E., Ketterling, R., Melnick, A., Greenberg, P. L., Herman, J., Juckett, M., Wang, E. S., Smith, M. R., Malick, L., Paietta, E., Czader, M., Litzow, M., Gabrilove, J., Erba, H. P., Gore, S. D., & Tallman, M. S.
Venue
Journal of Clinical Oncology
Published
2014-04-20
Volume
32
Issue
12
Pages
1242-1248
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2125347906
Cited by
246
References
2
FWCI
22.04
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Prolonged Administration of Azacitidine With or Without Entinostat for Myelodysplastic Syndrome and Acute Myeloid Leukemia With Myelodysplasia-Related Changes: Results of the US Leukemia Intergroup Trial E1905. https://app.cochat.ai/papers/10.1200/jco.2013.50.3102
The paper
Prebet, T., Sun, Z., Figueroa, M. E., Ketterling, R., Melnick, A., Greenberg, P. L., Herman, J., Juckett, M., Wang, E. S., Smith, M. R., Malick, L., Paietta, E., Czader, M., Litzow, M., Gabrilove, J., Erba, H. P., Gore, S. D., & Tallman, M. S. (2014). Prolonged Administration of Azacitidine With or Without Entinostat for Myelodysplastic Syndrome and Acute Myeloid Leukemia With Myelodysplasia-Related Changes: Results of the US Leukemia Intergroup Trial E1905. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2013.50.3102

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.